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The association of antidepressant medication and body weight gain
Abstract
Objective: To review the literature and discover which antidepressants are responsible for weight gain and
then to discuss the areas with lack of adequate knowledge.
Method: An electronic search was conducted through Medline, Pubmed, Cochrane library, and
ScienceDirect. Forty nine empirical researches were identified and reviewed.
Results: Amitriptyline, clomipramine, and mirtazapine have been associated with more weight gain induction
in clinical studies, but not in animal-based studies. All TCAs have been reported to cause weight gain except
protriptyline. MAOIs have been associated with weight gain. In SSRI group, citalopram and ecitalopram
induce weight, yet mixed results exist for paroxetine and fluoxetine. Researches unanimously reported weight
loss effect for bupropion. Some studies suggest contributing factors in the relationship of antidepressants with
body weight changes including age, gender, base-line weights and treatment duration. Various results of
different treatment durations have been reported in some cases but there are not continuous time-dependent
studies for the influences of antidepressants on body weight changes.
Conclusion: More studies are required to discover underlying mechanisms and the time-dependent effects of
antidepressants on body weight changes.
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Abstract: Objective: To review the literature and discover 
which antidepressants are responsible for weight gain and 
then to discuss the areas with lack of adequate knowledge. 
Method: An electronic search was conducted through 
Medline, Pubmed, Cochrane library, and ScienceDirect. 
Forty nine empirical researches were identified and reviewed. 
Results: Amitriptyline, clomipramine, and mirtazapine have 
been associated with more weight gain induction in clinical 
studies, but not in animal-based studies. All TCAs have been 
reported to cause weight gain except protriptyline. MAOIs 
have been associated with weight gain. In SSRI group, 
citalopram and ecitalopram induce weight, yet mixed results 
exist for paroxetine and fluoxetine. Researches unanimously 
reported weight loss effect for bupropion. Some studies 
suggest contributing factors in the relationship of 
antidepressants with body weight changes including age, 
gender, base-line weights and treatment duration. Various 
results of different treatment durations have been reported in 
some cases but there are not continuous time-dependent 
studies for the influences of antidepressants on body weight 
changes. Conclusion: More studies are required to discover 
underlying mechanisms and the time-dependent effects of 
antidepressants on body weight changes. 




Psychotropic drugs have various side effects and body weight 
gain is one of the known side effects for a number of 
medications in this group. There is extensive empirical 
evidence displaying the relationship between antipsychotic 
therapy and body weight gain. More precisely second-
generation antipsychotics (SGAs) are known for their 
potential to cause significant body weight gain.(1) Yet there 
exists a dearth of evidence regarding the effect of 
antidepressants upon body weight changes, compared to 
antipsychotics and further controversies pertaining to the 
effect of antidepressant on weight changes remain.(1) 
 
Depression and obesity are two common health problems in 
modern society.(2,3) There are studies suggesting a positive 
association between depression and obesity.(4-7) Some 
researchers have attempted to establish the underlying 
mechanisms for the positive association between obesity and 
depression.(4,6,8-11) Wild et al (4), McCarty et al (8), and 
Ball et al (9) suggested that women are more prone to 
become obese during depression compared to men. Heo et al 
(10) found gender, age, and race as contributing factors for 
the association of obesity and depression. Social and cultural 
factors may also contribute to the weight gain and obesity 
occurred in mood disorders.(6) Afari et al (11) investigated 
whether shared genetic influences are responsible for the 
association between these two conditions and they found a 
modest phenotypic association between depression and 
obesity. Antidepressant drugs have also been found to be the 
potential reasons for weight gain induction in depressed 
patients.(5,12,13)  
 
Among antidepressants TCAs (Tricyclic antidepressants), 
MAOIs (Monoamine oxidase inhibitors), and mirtazapine are 
known to have more problems related to weight gain.(14) 
Some patients can also gain weight while taking SSRIs, 
particularly paroxetine.(15) The aim of this article is to 
undertake a comprehensive review of the literature regarding 
the effect of antidepressants upon body weight changes, to 
clarify if weight gain occurs frequently on antidepressant 
usage and which antidepressants are associated with weight 
gain. The available studies will be categorized according to 
each antidepressant in order to achieve a general perspective 
about the effect of each antidepressant on body weight 
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changes. Finally the areas with deficient knowledge in the 
field of antidepressant medication and the weight gain 




An electronic search was conducted through Medline, 
Pubmed, Cochrane library, and Science Direct for the 
literature published between January 1973 and August 2012 
with two groups of key words: antidepressants, the names of 
each particular antidepressant and antidepressant categories 
as the first group, and obesity and weight as the key words of 
the second group. The articles identified in the search 
procedure were reviewed and the reference lists of reviewed 
articles were manually searched. References identified as 
relevant were retrieved and reviewed. After reviewing all of 
the studies, those which did not have any contents about 
association between antidepressants and weight changes were 
excluded. The remaining articles all concluded the target 
content either as the main result or as the secondary result. 
Among these articles, forty nine empirical studies were 
identified among which some applied mixture of 
antidepressants without any discriminations and some used 
each particular antidepressant in separate groups. The latter 
group which contains more precise results for each specific 




Forty nine empirical studies exist among literature regarding 
the effect of the antidepressants on body weight changes. 
Each antidepressant is discussed separately according to the 
relevant literature. Table 1 illustrates the summary of the 
results which have been achieved thorough the review. 
 
Amitriptyline 
Amitriptyline is the mostly reported antidepressant to cause 
weight gain.(12,13,16-22) In a clinical trial 51 depressed 
women being treated by amitriptyline were divided into two 
groups; one group maintained on amitriptyline for nine 
months and another group had the medication withdrawn 
after three months. Both groups gained weight during 
recovery. Yet the amitriptyline group continued to gain 
weight excessively, while the drug withdrawal after nine 
months treatment caused weight loss.(16) The result of 
another six-week randomized double-blind trial showed 
significantly higher body weight gains for taking 
amitriptyline than placebo and trazodone (the latter caused 
slight weight loss).(17) Pande et al (18) discovered that 100% 
of the patients receiving amitriptyline during their treatment 
gained weight. Amitriptyline induces remarkable weight gain 
in the patients, which is more than the weight gain due to 
clomipramine and imipramine administration.(12) Another 
study reported modest weight increases (1.7±4.1 Kg) in 22% 
of patients being treated with amitriptyline in a double-blind 
placebo controlled trial.(20) Berilgen et al (22) found that 
amitriptyline causes weight gain and increase in serum leptin 
levels and they suggested amitriptyline may cause leptin 
resistance. Conversely Hinze-Selch et al (21) did not find 
TCAs including amitriptyline to affect plasma leptin levels 
while these agents induced weight gain. 
 
Two animal-based experiments using Wistar rats (23) and 
OLETF rats (24) failed to mimic body weight gain due to 
amitriptyline medication and the study concluded that there 
was no linkage between weight gain and amitriptyline 
medication in rats.(23, 24) It shows that the available animal 
based studies for amitriptyline, could not model 
amitriptyline-induced weight gain observed in clinic. 
 
Clomipramine 
Clomipramine induces weight gain in human as supported by 
two clinical trials.(12, 25) On the contrary, clomipramine 
decreased weight gain and food intake in male Wistar rats 
maintained on a self-selection regime with separate sources 
of protein, fat and carbohydrate (macronutrient self-selection 
procedure).(26) During 27 days of this study clomipramine 
did not alter protein-rich or fat-rich diet consumption, yet it 
decreased energy intake as a result of a decrease in both 
carbohydrate-rich diet intake and body weight gain.(26) 
 
Imipramine 
Imipramine does not show the same potency to cause weight 
increase compared to amitriptyline and clomipramine. A non-
significant weight gain was the result of the majority of the 
studies.(27- 29) Mean weights of 2.1 ± 1.5 kg after 6 weeks, 
and 4 ± 1.4 kg after 4-6 months were gained in patients 
taking imipramine in a controlled trial which both amounts 
were less than the weight gain for other TCAs.(12) In an 
animal based experimental study weight gain was achieved 
and even continued after stopping administering imipramine 
to the rats.(30) 
 
Desipramine 
Fifty one percent of the patients taking desipramine in a 10-
year lasting clinical trial gained weight (18). Female Sabra 
mice also showed a gradual increase in their body weights 
while taking desipramine, compared to the placebo-
controlled group of the rats.(31) 
 
Nortriptyline 
All of the five available clinical trials for nortriptyline 
reported various degrees of weight gain in the patients taking 
this medication.(18,21,32-34) A group of researchers 
explored the efficacy and tolerability of nortriptyline in 35 
children and adolescents suffering from ADHD (Attention 
deficit hyperactivity disorder). One of their findings during 
their double-blind, placebo-controlled trial was that 
nortriptyline caused an average of 5.2 pounds weight gain 
through nine weeks of the study.(32) Hinze-Selch et al (21) 
found significant weight gains for amitriptyline/ nortiliptyline 
in their controlled clinical trial, while they did not report any 
increase in plasma leptin levels. In geriatric patients 
nortriptyline was not a potent weight gainer as significant 
amounts of weight gain (>10 lb) occurred in only 17.2% of 
the patients over 30-week period of the study.(34) Twenty 
four percent of the patients in the same study showed weight 




An average weight loss of 1.75 Ib per week was achieved for 
the patients being treated by protriptyline in a clinical trial 
investigating the influences of protriptyline on body weight 
changes of the patients who had low urinary level of 3-
methoxy-4-hydroxy-phenylglycol.(35) 
Maprotyline (Tetracyclic Antidepressant) 
As a result of a controlled clinical trial which was 
investigating the effects of different antidepressants on body 
weight changes maprotyline and amitriptyline induced the 
more marked weight gain whereas imipramine and non-
tricyclic antidepressants induced a smaller weight gain.(12) 
Maprotyline-treated patients gained a mean weight of 3.2 ± 
2.6 kg after 6 weeks and 5.2 ± 4.1 kg after 4-6 months.(12) 
 
Phenelzine and Tranylcypromine 
In the only available clinical trial investigating the influence 
of phenelzine on body weight changes, weight gain was 
achieved for forty six percent of the patients taking this agent 
for ten years (18).In the same study tranylcypromine induced 
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the largest increase in the weight (an average of 4.1 ± 2.2 Kg 
weight gain in the 73% of the patients) compared to other 
included antidepressants consisting of desipramine, 
nortriptyline, amitriptyline, and phenelzine.(18)  
 
Moclebomide 
The only available trial for the effect of moclebomide on 
body weight changes concluded just a non-significant weight 
gain as a result of taking this medication during both short-
term (6 weeks), and long-term (18 weeks) treatment.(19) 
 
Fluoxetine 
Inconsistent results exist among literature regarding the effect 
of fluoxetine on body weight changes. Some researchers 
reported weight loss for applying fluoxetine (19, 35- 38), and 
some found this agent to inhibit food intake in rats (39). 
Conversely other researchers discovered that fluxetine can 
provoke weight gain (30,40), or may not cause any changes 
in body weight.(24) Michelson et al (41) also searched for the 
effect of fluoxetine on body weight changes and detected 
both weight loss and weight gain during the acute and 
chronic phases of the treatment, respectively. During this 
one-year lasting clinical trial with 839 participants of 
depressed patients, modest weight loss happened after initial 
4 weeks for patients taking fluoxetine.(41) In continuing 
phase and after remission of depressive symptoms all patients 
gained weight and these were similar in both fluoxetine and 
placebo consumed patients. Therefore this can be due to the 
remission and not necessarily the medication.(41) Another 
study which found counter results for fluoxetine was carried 
out according to the baseline weights of the depressed 
patients.(42) This study discovered weight loss for 
overweight patients as a result of fluoxetine treatment, and 
body weight gain for normal weight group.(42) 
 
Fluvoxamine 
In a double-blind study, Moon and Jesinger (43) compared 
side effects of fluvoxamine and mianserin in 59 depressed 
patients. As a result fluvoxaomine did not cause any weight 
gain as a side effect while mianserin induced weight gain in 
the same study.(43) In another study with 40 participants of 
obese women, fluvoxamine caused mean weight loss of 3.1 
kg during 12 weeks which was greater but not significantly 
different from placebo controlled group.(44) 
Correspondingly fluvoxamine does not induce weight gain 




Paroxetine is another antidepressant which different results 
have been achieved for its influences on body weight 
changes. It can cause weight gain as supported by two 
randomized clinical trial.(37,45) Benkert et al (41) 
investigated the efficacy and tolerability of mirtazapine 
versus paroxetine and found that both drugs induced weight 
increases after 6 weeks in depressed patients and this effect 
was stronger for mirtazapine compared to paroxetine. Body 
weight changes of 284 patients with major depressive 
disorder who were randomly assigned to double-blind 
treatment with fluoxetine, sertraline, and paroxetine were 
analyzed in a clinical trial.(37) Significant weight increases 
only occurred in paroxetine group during a total of 26 to 32 
weeks.(37) Contrarily paroxetine was not found to induce 
any statically significant weight increases in depressed 
patients during a comparative retrospective study which used 
clinical records of double-blind trials.(19) Another study 
which concluded paroxetine does not affect body weight is a 
clinical trial at which Hinze-Selch et al(21) investigated the 
effects of several antidepressants on body weight, plasma 
leptin levels, TNF-a, and soluble TNF receptors. The writers 
reported that paroxetine did not make any changes in the 
mentioned factors including body weight which was similar 
to drug-free treatment effects, but opposite to TCAs 
treatment which caused increases in body weight and plasma 
leptin levels.(21) For animal based studies it is suggested that 




Wade et al conducted two 12-month trials: (i) a double-blind, 
randomized trial of placebo, citalopram, and clomipmmine in 
279 patients with panic disorder, and (ii) open trial of 
citalopram in 541 depressed patients. In the panic trial, 
citalopram-treated patients did not approach statistically 
significant weight gain and in the depression trial citalopram 
also caused no weight gain or a slight weight gain (<2.5 kg) 
in majority of patients.(25) Authors suggested that the 
minimal weight increases observed in the depressed patients 
may be a result of patients' appetites increasing as their 
condition improved.(25) Citalopram was also a cause of non-
significant weight gain in another clinical trial.(46) Among 
18 patients who were observed for carbohydrate craving due 
to treatment with citalopram (SSRI) in a mood disorder 
clinic, eight cases showed a significant increase in 
carbohydrate craving together with weight gain shortly after 
initiation of treatment.(47)  
 
Escitalopram 
During eight-months period of a double-blind clinical trial 
patients who were receiving escitalopram gained an average 
weight of 1.38 kg which was more than the weight gain in 
duloxetine-treated patients.(48) A non-significant weight 
gain of 0.14 kg over 6 months was the result of another part-
randomized open trial.(33)  
 
Sertraline 
Sertraline can induce a modest weight gain in depressed 
patients.(37) Conversely obese patients can lose weight by 
taking sertraline particularly those who have low urinary 
MHPG (3-methoxy-4-hydroxyphenylglycol).(49) 
Meyerowitz and Jaramillo (1994) carried on a clinical trial to 
find out the effect of sertraline on the body weight of 23 
depressed and overweight patients while measuring their 
urinary concentrations of 3-methoxy-4-hydroxyphenylglycol 
(MHPG). Results showed that sertraline can cause weight 
loss and with an average weight loss of 1.06 lb/week in 
patients with low urinary levels of MHPG which was found 
to be significantly greater than the average weight loss of 




The only available study reported that zimelidine caused no 
weight gain and, in many cases, weight loss was 
demonstrated with a mean weight change of 0.2 ± 1.8 kg 
during one month of applying this antidepressant in a 
randomized clinical trial.(50) 
 
Duloxetine 
During a double blind controlled trial, duloxetine had 
significantly greater incidence of treatment-emergent 
abnormal weight gain (> 7% increase in weight from 
baseline) compared with placebo.(48) During 10 controlled 
clinical trials the effect of duloxetine on body weight of 
patients with major depressive disorder was analyzed.(51) 
The results of these trials indicated no consistent effect of 
Duloxetine on weight as the patients treated with this drug 
experienced modest weight loss in acute phase following by a 





In a double-blind, six-week study, Moon, and Jesinger (43) 
investigated the effectiveness of mianserin and fluvoxamine 
in patients suffering from major depressive episode, 
mianserin affected compliance due to weight gain over 
longer period.  
 
Mirtazapine 
Mirtazapine has been reported in several studies to produce 
weight gain in humans.(20,45,46,52) During a double-blind 
placebo-controlled study in adult patients with major 
depressive disorder, the efficacy of mirtazapine was 
compared to amitriptyline. One of the findings of this study 
was that measured weight gain was more frequent with 
amitriptyline (22% of patients) compared with mirtazapine 
(13% of patients).(20) Another comparison was made 
between the efficacy and tolerability of mirtazapine versus 
paroxetine in 275 depressed outpatients. Patients were 
randomly assigned to 6 weeks of treatment with mirtazapine 
or paroxetine. The result regarding weight gain showed the 
more weight increase in the mirtazapine-treated group 
compared to paroxetine-treated group.(45) A multicenter 
randomized double-blind trial with the aim of comparing 
efficacy and tolerability of mirtazapine and citalopram in 
depressed patients yielded that mirtazapine-treated patients 
have significantly more increased appetite and body weight 
increase (8.8% and 15.3%) than citalopram-treated patients 
(1.5% and 4.5%).(46) Laimer et al investigated the influence 
of mirtazapine treatment on body weight, body fat mass, 
glucose metabolism, lipoprotein profile, and leptin in a group 
of seven depressed women compared to seven mentally and 
physically healthy female volunteers as a control group. 
Results confirmed that mirtazapine significantly increases the 
body weight (from a mean of 63.6 ± 13.1 kg to a mean body 
weight of 66.6 ± 11.9 kg), body fat mass, and leptin 
concentration of the patients.(52) In contrast with human 
based studies, there were no direct linkages between the 
development of obesity and mirtazapine according to the 
animal based controlled study carried on by Jeon, Joe, and 
Kee (24) who used OLETF (Otsuka Long-Evans Tokushima 
Fatty) rats for their study. 
 
Bupropion 
Three randomized clinical trials have investigated the effects 
of bupropion on body weight changes. In all of these studies, 
researchers concluded that bupropion can induce weight loss 
in patients.(53-55) In a randomized double-blind trial, modest 
mean weight losses with long-term bupropion SR treatment 
was achieved in patients with depression which increased 
with increasing baseline body weight.(53) Another 
randomized, double-blind, placebo-controlled study 
evaluated the efficacy bupropion SR in reducing weight and 
depressive symptoms in 422 obese adults with depressive 
symptoms. After 26 weeks, the bupropion SR group lost a 
greater average amount of weight (4.4 kg: 4.6% of baseline 
weight) compared to the placebo (1.7 kg: 1.8% of baseline 
weight).(54) The third 48-week double-blind, placebo-
controlled trial showed bupropion SR in conjunction with a 
lifestyle intervention program was associated with a dose-
related reduction in body weight.(55) 
Trazodone 
 
In a 6-week randomized double-blind research trazodone was 
found to cause a slight weight loss in the over-weight 
depressed patients. (17) 
 
Discussion: 
Significant positive association has been reported between 
depression and obesity more markedly among women.(56) 
Body weight gain is a known side effect for number of 
psychotropic drugs including antidepressants.(57) This 
review acknowledges the various and inconsistent effects of 
different antidepressants on body weight changes. TCAs and 
particularly amitriptyline are well known to cause weight 
gain among antidepressants.(18,58,59) Current review has 
also revealed that amitriptyline has been repeatedly reported 
as a weight gain inducer in clinical studies.(12,13,16- 22) All 
TCAs seems to cause weight gain in clinical studies except 
protriptyline which caused weight loss when administered to 
patients with major depression.(35) SSRI were thought to 
induce weight loss rather than weight gain in contrast to 
TCAs.(58) As seen among the results, the majority of studies 
reported weight loss for fluoxetine-treating patients, yet 
weigh gain has been also found for fluoxetine in some 
researches. The same inconsistent results apply to paroxetine. 
Weight gain has been also achieved in the studies using other 
SSRIs including citalopram and ecitalopram. Available 
researches for MAOIs reported weight gain for phenelzine 
and Tranylcypromine, but not any significant weight changes 
for moclebomide. Bupropion is the only antidepressant which 
all the studies confirm weight loss induction in depressed 
patients being treated with this agent. 
Some studies suggested that weight gain can be at least in 
parts due to the remission from depression itself and not 
necessarily as a result of antidepressant medication.(25, 60) 
The fact that losing appetite is one of the important signs of 
depression supports this idea. However there are evidences 
that antidepressants cause weight gain in patients with other 
psychiatric disorders such as ADHD (32) and migraine.(22) 
The duration of the treatment is also an important factor that 
may affect the results. Number of studies found differences 
among short-term and long-term effects of antidepressants on 
body weight changes. Michelson et al (41) reported weight 
loss for patients taking fluoxetine during the acute phase (4 
weeks), and weight gain for the same patients in continuing 
phase. Another study comprising of 10 clinical trials 
investigating doluxetine effects found also weight loss and 
weight gain in acute and chronic treatment phases 
respectively, but in non-significant and modest amounts. The 
categorization of acute-chronic and short-term, long-term 
phases is not the same among different studies considering 
the time-dependent effects of antidepressants and it adds 
more difficulties for interpreting the results as a general point 
of view. 
Age is another factor that seems to affect the relationship 
between antidepressant medication and body weight gain. As 
seen in the study conducted by Corman et al (34) 
nortriptyline was not a potent weight gainer in geriatric 
patients and it caused even weight loss in some of the 
subjects. It is contrary to non-elder patients among whom 
nortrptyline shows more potency to induce weight 
gain.(18,21,32) 
Base line weights of the patients can also impart in the final 
results of the weight changes due to antidepressant 
medication. This was confirmed in a clinical trial conducted 
by Orzack et al (42) who discovered weight gain among 
patients with normal weight, but weight loss in overweight 
patients when they were treated by fluoxetine. 
The inconsistent results for the effects of antidepressants on 
body weight changes which have been identified from the 
current review can be related to the concurrent psychotropic 
medication which happens in co-morbid psychiatric patients. 
This phenomenon can also be due to different designs, 
sample sizes, and duration of the studies or as a result of 
other contributing factors such as genetic vulnerability in 
addition to the factors mentioned before. 
Obesity and overweight condition may lead to serious health 
problems such as cardiovascular diseases. Moreover weight 
gain caused by antidepressant drugs is a major reason for 
patients’ noncompliance with treatment and poor treatment 
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outcome and fighting weight gain once it has occurred can be 
very difficult.(57) Therefore understanding the underlying 
mechanisms that contribute to the effect of antidepressants on 
body weight changes is important. 
The results of animal based studies are not always consistent 
with the clinical ones. For instance amitriptyline and 
mirtazapine failed to have any direct association with obesity 
in rats and in fact it was suggested by Jeon et al (24) that 
these two antidepressants may regulate circulating levels of 
adiponectin and adiponectin receptor. Amitriptyline has been 
also found to be unsuccessful in increasing daily food intake 
and body weight of the rats in series of experimental studies 
despite applying various dosages, route of administration, 
diet composition and palatability.(23) Clomipramine was 
chronically administered to male wistar rats exposing to 
macronutrient self-selection procedure and it decreased food 
consumption and body weight gain (26) while similar to 
amitriptyline and miratazpine, clomipramine induces weight 
gain in cliniucal studies.(12,25) Interpreting the results of 
animal models for producing obesity after antidepressant 
medication is challenging when considering the real life 
situations for human. Mastronardi et al (30) tried to model 
the similar situation of patients experiencing stress/ 
depression and exposure to short-term antidepressant 
medication continuing by high-fat diet consumption in the 
rats. For achieving this kind of experiment, repeated restraint 
stress (RRS) and short-term antidepressant medication were 
applied to the rats following by exposure to high-fat diet for a 
long time.(30) Results showed weight gain effects even after 
discontinuing the antidepressants consisting of imipramine 
and fluoxetine in rats which supported the time-dependent 
sensitization phenomenon.(30) In another animal based 
experimental study desipramine first provoked weight loss in 
the rats following by weight gain in continuing phases of 
treatment lasting for more than 3 months.(31) 
Many regulatory substances have been known to affect 
appetite behavior including neurotransmitters such as 
noradrenaline, 5HT, neuropeptides such as cholecystokinin, 
corticotropin releasing factor, neuropeptide Y, and opioids 
and other hormone-like peptides such as enterostatin, 
bombesin, amylin, and leptin (59). TCAs have been reported 
to associate with weight gain due to their antagonizing action 
on H1 receptors for many years.(61) It has been suggested 
that the weight gain induction of citalopram can also be due 
to its high affinity to H1 receptors.(61) Some researchers 
attempted to find the role of leptin in the association of 
antidepressants and obesity.(21, 22) Berilgen et al (22) 
discovered that amitriptyline may cause leptin resistance 
possibly by different mechanisms and thereby result in 
increases in serum leptin levels and BMI. Conversely in 
another study amitriptyline did not cause any increases in 
leptin levels while inducing weight gain.(21) The underlying 
mechanisms for weight gain results of antidepressant 
medication is not yet well understood and further studies are 
required for investigating the role of neurotransmitters and 
other possible contributing factors in the process of gaining 
weight due to antidepressant medication. The areas of 
controversies such as the opposite results reported in human 
versus animals based studies or the different time-dependent 
effects of antidepressants on body weight changes need to be 
addressed in future studies. More continuous and more 
precise time-dependent investigations of the influences of 
antidepressants such as what has been done for 
antipsychotics (61), can help to clear the role of the treatment 
duration in producing weight gain concurrent with 
antidepressant medication. Investigating the effects of other 
antidepressants which have not been included in previuos 
studies such as doxepin, trimipramine, venlafaxine, 
nefazodone, and amoxapine is another issue which needs to 
be considered in the relevant future studies regarding the 
association of antidepressant medication and body weight 
changes. 
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Table 1: Effects of antidepressants on body weight 
Name of the 
Antidepressant 
Design of the Study Results Reported Amounts in the Results 
References and 
the Year of the 
Publications 
Amitriptyline 
Randomized double-blind - 6 weeks Weight gain 
 
17, 1986 
Randomized clinical trial - One month Weight gain 
>10 Ib in 28%; 7-10 lb in 44%; 3-6 Ib in 17%; No change in 
11% 
13, 1998 
Clinical trial Weight gain 100% of patients (n=5) 18, 1989 
Controlled trial Weight gain After 6w: 3.2+-3.1 kg; After 4-6m: 6.2+-7.1 kg 12, 1994 
Retrospective study of double blind 
trials 
Weight gain In both 6week and continuing 18 weeks duration. 19, 1995 
Double-blind placebo controlled trial Weight gain 22% of patients; Mean increase: 1.7 ± 4.1 Kg 20, 1998 
Controlled trial Weight gain 3.5 ± 1.1 kg for amitriptyline/ nortriptyline 21, 2000 
Clinical trial Weight gain and increased leptin level 
 
22, 2005 
Animal based experimental study 
(Wistar rats) 
No change in weight and food intake 
 
23, 1987 
Animal based experimental study 
(OLETF rats) 
No direct linkage with obesity 
 
24, 2008 




Clinical trial - 4months (16 weeks) 
Weight gain but, not associated with 
rapid weight gain 
Mean average of 5 lb weight gained in all subjects; 19%: 6-10 
lb weight increase; 9%: 11-15 Ib weight increase; 6%: gained > 
15 Ib; 6%: 6-10 lb weight loss 
27, 1986 
Clinical trial - 33 weeks Not significant changes 
Weight changes of: 1.3 ± 5.3 lb for acute phase (9.5 weeks); 3.1 
± 7.8 lb for continuing phase (2.3 weeks) 
28, 1990 
Randomized clinical trial - 8weeks 




Weight gain (less than other included 
TCAs) 
After 6 w: 2.1 ± 1.5 kg; After 4-6 m: 4 ± 1.4 kg 12, 1994 
Animal based experimental study (Male 
Sprague-Dawley rats) 
Weight gain even after discontinuing 
the medication  
30, 2011 
Nortriptyline 
Clinical trial Weight gain 62% of patients gained weight 18, 1989 
Double-blind, placebo-controlled trial Weight gain Average of 5.2 lb in 9 weeks 32, 2000 
Controlled clinical trial Weight gain 3.5 ± 1.1 kg for amitriptyline/nortriptyline 21, 2000 
Part-randomized open-label study Weight gain 1.82 kg after 6 months 33, 2011 
Clinical trial Weight gain Overall mean weight gain in 30 weeks: 3.92 ± 10.34 34, 1992 
Desipramine 
Clinical trial - ten years Weight gain 51% of patients gained weight 18, 1989 
Animal based experimental (Female 
Sabra mice) 
Weight gain, gradually increase in 
chronic treatment  
31, 2006 
Protriptyline Clinical trial Weight loss Average weight loss: 1.75 lb/w 35, 1992 
Clomipramine 
Controlled trial - 4-6 months (6w- 4-
6m) 
Weight gain After 6 w: 1.9 ± 3.4 kg; After 4-6m: 6.1 ± 6.3 kg 12, 1994 
a double-blind, randomised trial Weight gain 
 
25, 1999 
Animal based experimental, 27 days 
(Male Wistar rats) 
Decrease food intake and weight 
 
26, 2007 
Maprotyline (TeCA) Controlled trial Weight gain After 6 w: 3.2 ± 2.6 kg; After 4-6m: 5.2 ± 4.1kg 12, 1994 
Fluoxetine 
Clinical trial (6 patients, 9.8 months) Weight gain Average weight gain: 20 lb 40, 1991 
Clinical trial Wight loss Average weight loss of 1.20 lb/w 35, 1992 
Double-blind trials Weight loss 
 
19, 1995 
Double-blind parallel study Weight loss 
 
36, 1996 
Randomized clinical trial Modest but non-significant weight loss 
 
37, 2000 




At acute phase (4weeks): Mean absolute weight loss of 0.4 kg; 
At continuing phase, mean weight gain of: 26 w: 1.4+-3.2 kg; 
38 w: 3.1+-3.8 kg; 50 w: 4.3+-5.3 kg 
41, 1999 
Clinical Trial Weight loss; Weight gain 
Weight loss in overweight patients; Weight gain in ideal weight 
patients 
42 
Animal based experimental study 
(OLETF rats) 
No linkage with weight gain 
 
24, 2008 
Animal based experimental study (Male 
Sprague-Dawley rats) 
Weight gain even after discontinuation 
 
30, 2011 




Randomized clinical trial Weight gain 
 
45, 2000 
Randomized clinical trial Significant weight increase 
 
37, 2000 
Double-blind trials No change in weight 
 
19, 1995 
Controlled clinical trial No change in weight, and leptin level 
 
21, 2000 




Clinical trial Weight loss 
Average weight loss of: 1.06 lb/week in those with low urinary 
MHPG; 0.42 Ib/week in those with high urinary MHPG 
49, 1994 
Randomized clinical trial 




Clinical trial with 8 patients 
Significant weight gain and increasing 
carbohydrate craving  
47, 1996 
Multicenter randomized double blind 
trial 
Different adverse effects compared to 
mirtazapine 
Weight gain only in 4.5% of patients 46, 1999 
1. Double blind, randomized; 2. Open 
trial 





Double blind controlled trial Weight gain 1.38kg in 8 months 48, 2007 
Part-randomized open-label study Not significant weight change Average of 0.14 kg weight increase in 6 months 33, 2011 
Fluvoxamine 
Double blind trial No weight gain 
 
43, 1991 
Double-blind placebo controlled Weight loss Overall mean weight loss of 3.1 kg in 12 weeks 44, 1986 
Zimelidine Randomized clinical trial No weight gain Mean weight change in one month: 0.2 ± 1.8 kg 50, 1988 
Phenelzine Clinical trial Weight gain In 46% of patients 18, 1989 
Tranylcypromine Clinical trial Weight gain In 73% of patients (4.1 ± 2.2 Kg) 18, 1989 









Weight loss Mean weight loss: 4.4 kg (4.6% of baseline weight) in 26 weeks 54, 2002 
Double blind placebo controlled trial Dose-related reduction in weight 
24-week weight loss (% of baseline body weight): 7.2% for SR 
300; 10.1% for SR 400; 
48-week weight loss: 7.5% for SR 300; 8.6% for SR 400 
55, 2002 
Trazodone Randomized double-blind study 




Double blind controlled trial Weight gain 0.6kg in 8 months 48, 2007 
10 controlled clinical trials No consistent weight change No significant differences from placebo groups 51, 2006 




Double-blind placebo controlled Weight gain Average of 1.4 ± 3.1 kg 20, 1998 
Multicenter randomized double blind 
trial 
Different adverse effects compared to 
citalopram 
15.3% of patients gained weight 46, 1999 
Randomized clinical trial Weight gain 
 
45, 2000 
Clinical trial Weight gain Weight increased from 63.6 ± 13.1 kg to 66.6 ± 11.9 kg 52, 2006 
Animal based experimental study 
(OLETF rats) 
No linkage with weight gain 
 
24, 2008 
